DOX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Amdocs Ltd (DOX) does not present a strong buy opportunity for a beginner, long-term investor at this time. While the company has shown modest financial growth and resilience in its earnings, the lack of significant positive catalysts, bearish technical indicators, and hedge fund selling trends suggest a wait-and-see approach may be more prudent.
The MACD is positive and expanding, indicating a bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level of R1: 66.534, which may limit immediate upward movement.
The company announced a five-year renewal of its contract with T-Mobile, addressing a key investor concern. Financials show YoY growth in revenue (+4.13%), net income (+4.17%), and EPS (+9.02%). Analysts maintain a Buy/Overweight rating despite lowering price targets, citing resilience and strategic wins.
Hedge funds are aggressively selling the stock, with a 1713.29% increase in selling activity over the last quarter. Gross margin dropped by -3.58% YoY. The stock has bearish moving averages, and no recent news or congress trading data suggests a lack of immediate positive sentiment.
In Q1 2026, Amdocs reported revenue of $1.155 billion (+4.13% YoY), net income of $154.534 million (+4.17% YoY), and EPS of $1.45 (+9.02% YoY). However, gross margin declined to 35.79% (-3.58% YoY).
Barclays and Stifel lowered their price targets to $92 and $88, respectively, but maintained Overweight/Buy ratings. Analysts view the company's results as resilient, with strategic wins and a focus on double-digit earnings return policy.
